Potential breakout, major support/trend line to be testedThis stock has been showing a consistent uptrend setting higher highs and higher lows. It is approaching it's key support with the RSI also showing it to be undervalued. Worth a look.
1MRKX trade ideas
MRK-Short at 4 hr supply NYSE:MRK
MRK had a strong bearish correction at the start of the year and we believe that the stock price may continue to fall after a period of bullish rebound in 4hr.
However, do take note that if the stock's bullish rise breaks the high, then we will see the stock return to the strong bullish impulse.
Short ConditionsAfter the failure of a key support(blue zone), we have a return to it
probability of falling is very high
But you can wait for formation of a revarsal pattern And then sell it.
Good luck
$MRK bullish divergence before earnings$MRK bullish divergence with RSI at 0.61 fibonacci retracement. Merck & Co Inc (MRK) is scheduled to announce its earnings on Wednesday, February 5 before market opens. Daily chart.
Merck: Ichimoku Clouds on bullish setupIchimoku Clouds still confirm the bullish setup. Today's session will be important, if positive, to manifest further bullish intentions (Break of the $92.10 resistance).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings.
Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best!
We took a long position at $82.00 several weeks ago.
We feel the stock is worth at minimum, $150.00 all day long.
KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales.
Holding for the almost 3% Dividend and for the stock price appreciation into the future.
250,000 LONG @ $82.00
Best of Luck Everyone!
MRK - DAILY CHARTHi, today we are going to talk about Merck & Co. and its current landscape.
Merck & Co. shares are in evidence today as was unveiled that the company it's going to acquire ArQule for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established leadership on the Cancer-Drug Race, since the company has the top-selling immunotherapy drug Keytruda, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Merck & Co. - MRK - SHORTKeep it Simple!
Looking at MRK on the Daily there has been an easy setup for a short entry at the 87 range (Orange box). The frequent wicks into this range suggest that there are being fills made for short positions. I have set three profit targets (Green boxes) for this trade, where I will almost completely out of the trade by the third profit target. The trade made very good risk to reward.
This trade is not too late for you to enter the short position, with a stop above the top of the range.
$MRK Beat and Raise for Merck, But!Prior to the earnings report the stock and chart was becoming tired, indicators were starting to head south, lets see if the pre market action can follow through today with a break towards all time highs.
Average analysts price target $95.12 | Buy
P/E 23.28
Company profile
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ
MRK Long w/ Earnings expectationsMRK was down 3.81% today just like precedent times before earnings.
Here's my analysis, the stock is going up this next days to join the channel support and with the earnings will go up again for a long swing.
***
This is MY analysis, it is not a recommendation.
***
MRKMRK looks good here up to 88. Safest entry is waiting on a retest of the channel around 80. Looks even better if you believe the market is going to sell-off after the fed cuts rates. Everything sells off in bear markets, but healthcare is a "safety" investment that typically a lot of people will put money into when the market starts to sell-off the first time off of ATH's. (2018 October and May 2019 for example)
Earnings are coming up though. Which means a high volume day either up or down. Being that we are sitting on the bottom side of this channel, be very careful not to get caught on an impulsive sell-off if that breaks. Being that all news is good news this earning season, this seems unlikely, but still possible.
*NOT Trade recommendations, Always do your own analysis!**
Look for Merck to respect trend line before enteringMerck ended the day near the bottom of its parallel channel, right above a high-volume support node at 8.19 and a trend line that's parallel with channel bottom. After hours, the price has moved below both the support and the trend line, but in my experience, after hours moves don't necessarily mean much. The real test will be tomorrow after market open. If the trend line breaks, then the price will test the bottom of the channel. That will be an opportunity for an entry with a tight stop loss.
Merck had a product launch after hours today (a smart pet feeder) that could help move the price upward, but honestly this stock has so many catalysts that I'm not sure investors pay much attention to them anymore. This one is pretty minor in the scheme of things. More important factors are Merck's strong analyst ratings and long history of earnings beats. One possible downside catalyst is Merck's slightly negative Earnings Surprise Prediction from Zacks.
$MRK Merck & CO Inc. still in 19 year recovery cycleOn the daily chart of NYSE:MRK it seems that a nice breakout rally is setting up, with $84 as a good point to evaluate your position. The chart accompanying this post is merely a look at the nature of declines that a stock can suffer, to get back to the 2000 price level may take a possible 21 years, that is a long to hold and pray. It teaches us the lesson that stocks can keep going down, so accept you lose quickly and don't wait 20 years for it to claw its way back. Every company that we invest in is just one mistake or headline away from the fate of falling like a stone and the only ones left holding on are those who just couldn't accept the loss in the hope it will be different next week.
"even the mighty can fall"
AVERAGE ANALYSTS PRICE TARGET $88
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO 26
COMPANY PROFILE
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
